Chemotherapy uses medicines to destroy cancer cells or slow their growth. Treatment may be administered alone or alongside surgery, radiation or other therapies. The medicine, schedule and duration depend on the cancer type, stage and patient's overall health.
Cancer immunotherapy uses medicines that help the immune system recognise or attack certain cancers. It is appropriate only for selected diagnoses and may depend on tumour biomarkers. Treatment requires monitoring for immune-related adverse effects.
Targeted therapy acts on particular molecular features involved in cancer growth. Testing may help identify whether a tumour has a relevant target. Treatment selection depends on cancer type, molecular results and clinical suitability.
Precision oncology considers tumour characteristics, molecular markers and patient factors when planning cancer treatment. Molecular testing may identify relevant treatment options for selected cancers. The approach aims to personalise care while recognising that not every cancer has an actionable target.
Breast cancer management may involve chemotherapy, hormonal therapy, targeted treatment or immunotherapy depending on the tumour subtype and disease stage. Medical oncologists coordinate systemic treatment with surgical and radiation specialists where appropriate.
Systemic treatment for lung cancer may involve chemotherapy, immunotherapy or targeted medicines. Treatment decisions consider cancer subtype, stage, biomarker results and general health. Multidisciplinary assessment helps determine the most appropriate treatment sequence.
Medical treatment for gynaecological cancers may involve chemotherapy, targeted medicines or immunotherapy for selected patients. The approach depends on the affected organ, tumour characteristics and disease stage. Coordination with gynaecological oncology teams is important.
Gastrointestinal cancers affect organs such as the stomach, colon and rectum. Medical treatment may include chemotherapy or selected targeted and immune-based therapies. Planning depends on the cancer type, stage and biomarker findings.
Haematological malignancies include certain cancers affecting blood-forming tissues and lymphatic structures. Treatment varies by diagnosis and may include chemotherapy, immunotherapy, targeted medicines or transplantation-related assessment with specialist haematology teams.
Molecular profiling examines selected genetic and biological features of a cancer. Test results may help identify appropriate targeted treatments or clinical trial options. Testing is recommended according to tumour type and established clinical indications.
Advanced cancer care focuses on controlling disease, managing symptoms and maintaining quality of life. Depending on the diagnosis, treatment may include systemic cancer medicines, supportive care or symptom-directed interventions. Decisions consider clinical benefits and potential risks.
Palliative oncology care addresses pain, symptoms and quality-of-life concerns associated with cancer. It may be provided alongside active cancer treatment. Care includes assessment of physical and psychological needs and coordination with supportive medical teams.